Retroviral DNA-the silent winner: blood transfusion containing latent feline leukemia provirus causes infection and disease in naïve recipient cats by Nesina, Stefanie et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2015
Retroviral DNA-the silent winner: blood transfusion containing latent feline
leukemia provirus causes infection and disease in naïve recipient cats
Nesina, Stefanie; Katrin Helfer-Hungerbuehler, A; Riond, Barbara; Boretti, Felicitas S; Willi, Barbara;
Meli, Marina L; Grest, Paula; Hofmann-Lehmann, Regina
Abstract: BACKGROUND: The feline leukemia virus (FeLV) is a gamma-retrovirus of domestic cats
that was discovered half a century ago. Cats that are infected with FeLV may develop a progressive
infection resulting in persistent viremia, immunodeficiency, tumors, anemia and death. A significant
number of cats mount a protective immune response that suppresses viremia; these cats develop a regres-
sive infection characterized by the absence of viral replication and the presence of low levels of proviral
DNA. The biological importance of these latter provirus carriers is largely unknown. RESULTS: Here, we
demonstrate that ten cats that received a transfusion of blood from aviremic provirus carriers developed
active FeLV infections, some with a progressive outcome and the development of fatal FeLV-associated
disease. The infection outcome, disease spectrum and evolution into FeLV-C in one cat mirrored those of
natural infection. Two cats developed persistent antigenemia; six cats were transiently antigenemic. Re-
activation of infection occurred in some cats. One recipient developed non-regenerative anemia associated
with FeLV-C, and four others developed a T-cell lymphoma, one with secondary lymphoblastic leukemia.
Five of the ten recipient cats received provirus-positive aviremic blood, whereas the other five received
provirus- and viral RNA-positive but aviremic blood. Notably, the cats that received blood containing
only proviral DNA exhibited a later onset but graver outcome of FeLV infection than the cats that were
transfused with blood containing proviral DNA and viral RNA. Leukocyte counts and cytokine analyses
indicated that the immune system of the latter cats reacted quicker and more efficiently. CONCLU-
SIONS: Our results underline the biological and epidemiological relevance of FeLV provirus carriers and
the risk of inadvertent FeLV transmission via blood transfusion and demonstrate the replication capacity
of proviral DNA if uncontrolled by the immune system. Our results have implications not only for veteri-
nary medicine, such as the requirement for testing blood donors and blood products for FeLV provirus by
sensitive polymerase chain reaction, but are also of general interest by revealing the importance of latent
retroviral DNA in infected hosts. When aiming to eliminate a retroviral infection from a population,
provirus carriers must be considered.
DOI: 10.1186/s12977-015-0231-z
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-118168
Published Version
 
 
Originally published at:
Nesina, Stefanie; Katrin Helfer-Hungerbuehler, A; Riond, Barbara; Boretti, Felicitas S; Willi, Barbara;
Meli, Marina L; Grest, Paula; Hofmann-Lehmann, Regina (2015). Retroviral DNA-the silent winner:
blood transfusion containing latent feline leukemia provirus causes infection and disease in naïve recipient
cats. Retrovirology, 12(1):105. DOI: 10.1186/s12977-015-0231-z
2
Nesina et al. Retrovirology  (2015) 12:105 
DOI 10.1186/s12977-015-0231-z
RESEARCH
Retroviral DNA—the silent winner: blood 
transfusion containing latent feline leukemia 
provirus causes infection and disease in naïve 
recipient cats
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Abstract 
Background: The feline leukemia virus (FeLV) is a gamma‑retrovirus of domestic cats that was discovered half a cen‑
tury ago. Cats that are infected with FeLV may develop a progressive infection resulting in persistent viremia, immu‑
nodeficiency, tumors, anemia and death. A significant number of cats mount a protective immune response that 
suppresses viremia; these cats develop a regressive infection characterized by the absence of viral replication and the 
presence of low levels of proviral DNA. The biological importance of these latter provirus carriers is largely unknown.
Results: Here, we demonstrate that ten cats that received a transfusion of blood from aviremic provirus carriers 
developed active FeLV infections, some with a progressive outcome and the development of fatal FeLV‑associated 
disease. The infection outcome, disease spectrum and evolution into FeLV‑C in one cat mirrored those of natural 
infection. Two cats developed persistent antigenemia; six cats were transiently antigenemic. Reactivation of infection 
occurred in some cats. One recipient developed non‑regenerative anemia associated with FeLV‑C, and four others 
developed a T‑cell lymphoma, one with secondary lymphoblastic leukemia. Five of the ten recipient cats received 
provirus‑positive aviremic blood, whereas the other five received provirus‑ and viral RNA‑positive but aviremic blood. 
Notably, the cats that received blood containing only proviral DNA exhibited a later onset but graver outcome of FeLV 
infection than the cats that were transfused with blood containing proviral DNA and viral RNA. Leukocyte counts and 
cytokine analyses indicated that the immune system of the latter cats reacted quicker and more efficiently.
Conclusions: Our results underline the biological and epidemiological relevance of FeLV provirus carriers and the 
risk of inadvertent FeLV transmission via blood transfusion and demonstrate the replication capacity of proviral DNA 
if uncontrolled by the immune system. Our results have implications not only for veterinary medicine, such as the 
requirement for testing blood donors and blood products for FeLV provirus by sensitive polymerase chain reaction, 
but are also of general interest by revealing the importance of latent retroviral DNA in infected hosts. When aiming to 
eliminate a retroviral infection from a population, provirus carriers must be considered.
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Background
The feline leukemia virus (FeLV) is a retrovirus that 
occurs worldwide in domestic cats and some related 
small felids [1, 2]. FeLV infection can induce cytoprolif-
erative (tumors) and cytosuppressive (immunodeficiency, 
anemia) diseases with fatal outcomes. FeLV isolates are 
categorized into several subgroups according to their 
viral receptor usage and interference capabilities. FeLV-
A is the common subgroup, which is horizontally trans-
mitted, highly contagious, but low in pathogenicity [1, 
3]. FeLV-A infected cats may develop diseases, such as 
lymphoma mainly of T-cell origin. FeLV-B and FeLV-
C arise within FeLV-A infected cats by recombination 
with endogenous FeLV-like sequences (enFeLV) and via 
mutations or insertions in the surface glycoprotein gene, 
respectively [4, 5]. FeLV-B is found in ~50 % of the FeLV-
infected cats, whereas FeLV-C develops in only ~1 % of 
FeLV infections and is strongly associated with the devel-
opment of non-regenerative anemia [3, 6, 7]. Further-
more, FeLV-T, a T-cell tropic cytopathic virus that causes 
lymphoid depletion and immunodeficiency, may develop 
from FeLV-A in infected cats via mutations and inser-
tions in the surface glycoprotein gene [8]. Finally, most 
recently a FeLV-D subgroup was described; FeLV-D are 
recombinant viruses that arise after transduction of the 
envelope gene of feline endogenous gammaretrovirus, 
ERV-DC, into FeLV [9].
There are a variety of outcomes from FeLV infection, 
which are not only influenced by the strain, subtype and 
dose of the virus but also by different host factors, such 
as the age and immune system status of the infected cat 
[1]. The spectrum of different infection outcomes is clas-
sified according to results from FeLV antigen (p27) and 
nucleic acid detection and serology into abortive, regres-
sive, progressive or atypical infections [10–13]. Detection 
of the p27 antigen is a parameter for viremia in most cats 
[14]. In addition, latent non-productive infection, char-
acterized by the absence of viremia and the persistence 
of the virus in the bone marrow, can be identified in cats 
following regressive infection [15, 16]. Latent infection 
is detected by the prolonged cultivation of bone marrow 
cells in the presence of hydrocortisone [16] and usually 
resolves within a few months of exposure to FeLV but 
has been detected in some cats up to 30  months after 
infection [17]. Although persistently infected cats fail to 
develop a successful immune response to FeLV and suc-
cumb to FeLV-associated diseases, cats with regressive 
infections (previously also referred to as “recovered cats”) 
[18] mount a cellular and humoral immune response to 
FeLV and overcome viremia usually after a few weeks; 
however, these cats typically remain provirus-positive for 
the remainder of their lives [19]. The prevalence of provi-
rus positive and p27-negative cats varies among different 
investigated populations and has been observed to be 
as high as 10  % [19, 20]. The clinical importance of the 
provirus positive status is not completely understood but 
may contribute to a long-lasting maintenance of protec-
tive immunity against FeLV [21]. However, reactivation 
of the infection with development of FeLV-associated 
diseases has been documented in many provirus positive 
cats [11, 15, 16, 22, 23].
FeLV is transmitted horizontally, mainly via saliva from 
persistently infected cats but also vertically from infected 
queens to their kittens. The virus is also detectable in 
feces, urine, milk and blood [24–28]. Iatrogenic transmis-
sion of FeLV may occur via the transfusion of blood from 
FeLV viremic (p27 antigen-positive) blood donors [29], 
and blood recipients may be particularly prone to infec-
tion and FeLV-associated disease due to pre-existing grave 
clinical conditions and possible immunosuppression. 
Common reasons for blood transfusion in cats include 
hemorrhages, lack of erythropoiesis and immune-medi-
ated hemolytic anemia [30]. Blood banks for cats have 
been developed, and the demand for high-quality blood 
products has increased [30, 31]. The screening of blood 
donors and products for infectious diseases is of increas-
ing importance. It is commonly recommended to test 
feline blood donors for FeLV infection by antigen detec-
tion [32]. So far, the risk of a FeLV transmission by trans-
fusion of provirus positive blood has not been evaluated. 
However, intradermal inoculation of plasmid deoxyribo-
nucleic acid (DNA) carrying the FeLV-A provirus (Rick-
ard/FRA) has resulted in productive FeLV infection [33]. 
Therefore, we hypothesized that whole blood containing 
white blood cells carrying the FeLV provirus will transfer 
the infection and result in full-blown infection in recipi-
ent cats. The aim of the present study was thus to test 
whether FeLV infection can be transmitted via the trans-
fusion of blood from a FeLV provirus positive and antigen 
negative blood donor to a naïve recipient cat.
Results
Transmission of FeLV by the transfusion 
of provirus‑positive blood
To test whether FeLV infection can be transmitted by the 
transfusion of provirus positive blood, 15 specified path-
ogen-free (SPF) kittens were each transfused with 10 mL 
of blood. Five kittens in group A (P1–P5) received blood 
from a provirus-positive cat (DP), five kittens in group 
B (R1–R5) received blood from a provirus- and viral 
RNA-positive cat (DR), and five cats in the control group 
C (N1–N5) received naïve blood from an SPF cat (DN; 
Table  1). All three blood donor cats tested FeLV-nega-
tive in virus isolation and negative for the p27 antigen. 
Blood samples were collected from the recipients prior 
to (week 0) and in weekly intervals after the transfusion 
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for 15 weeks. During and after the blood transfusion, no 
adverse reactions were observed in any of the recipients. 
According to the FeLV loads in the transfused blood, 
each cat in group A received a total of 1 × 104 provirus 
copies, and each recipient in group B received 6.25 ×104 
provirus and 6.2 × 105 viral RNA copies. The packed cell 
volume (PCV) of cat DR was 32  % at the time point of 
blood collection for transfusion; this value was used to 
calculate the viral RNA load per mL of whole blood as 
described in the “Methods” section.
All of the recipient cats in groups A and B became 
FeLV-infected after blood transfusion as judged by pro-
viral polymerase chain reaction (PCR) from peripheral 
blood and plasma viral RNA detected by reverse tran-
scriptase (RT-)PCR (Fig. 1). By contrast, all of the cats in 
the control group C remained FeLV-negative throughout 
the study. The cats in group B (receiving blood with pro-
virus and viral RNA) became FeLV provirus-positive sig-
nificantly earlier than did the cats in group A (receiving 
blood with the provirus only): in week 1 post transfusion, 
all of the cats in group B were already provirus posi-
tive, whereas none of the cats in group A were positive 
(pFisher = 0.0079; Fig. 1a, b). In the first 2 weeks after the 
transfusion, the proviral loads were significantly higher 
in group B than in group A (Fig. 1a, b; pMWU < 0.05). By 
contrast, in weeks 7–12 and 15, the proviral loads were 
significantly lower in the cats in group B than in those in 
group A (pMWU < 0.05; Fig. 1a, b).
All of the recipient cats in groups A and B also turned 
plasma viral RNA-positive (Fig.  1c, d). The plasma viral 
RNA loads were significantly higher in the cats in group B 
compared with those in group A 1 week post transfusion 
(pMWU = 0.0079; Fig. 1c, d). However, the cats in group 
B exhibited lower plasma viral RNA loads than did the 
cats in group A (significantly lower in weeks 4 and 7–11; 
pMWU < 0.05). By week 15 post transfusion, three cats in 
group B exhibited undetectable plasma viral RNA loads, 
whereas all of the cats in group A remained positive.
Ethylenediaminetetraacetic acid (EDTA)-anticoagu-
lated plasma samples were also analyzed for the pres-
ence of the FeLV p27 antigen as a marker for viremia by 
sandwich enzyme-linked immunosorbent assay (ELISA). 
All recipient cats in group A tested p27-positive at some 
time point after transfusion (Fig. 2). Two of the five cats 
in group A became persistently infected (progressive 
infection), and three cats developed a transient viremia 
and regressive infection (Fig.  3a). All of the five cats in 
group B developed regressive infection, three with tran-
sient viremia but low p27 values (max. 8 %) and two with 
undetectable antigenemia (Figs.  2, 3b). Four weeks post 
transfusion, significantly more cats were p27-positive in 
group A than in group B (pFisher = 0.0476; Fig. 2). When 
analyzing the p27 loads, the cats in group A exhibited sig-
nificantly higher p27 loads in weeks 8 and 9 after transfu-
sion than did the cats in group B (pMWU = 0.0317; Fig. 3).
Replicating virus, latent virus and viral shedding 
in recipient cats
Peripheral blood was collected in week 5 post transfu-
sion and tested for the presence of replicating virus using 
Table 1 Outcome of FeLV infection in the two FeLV-exposed blood donors and the ten exposed recipient cats
† euthanized/died
a Status observed until 149 weeks post transfusion
b Euthanized for humane reasons
c During follow-up study, without re-exposure to FeLV [35]
Group Cat Outcome of FeLV exposure Health status long‑term follow‑upa
Blood donors A DP Regressive infection, provirus‑positive Healthy
B DR Regressive infection, viral plasma RNA‑ and provirus‑
positive
†Week 60: reactivation of infection, multicentric T‑cell 
lymphomab
Recipients A P1 Progressive infection, persistently p27‑positive †Week 31: non‑regenerative anemia (FeLV‑C)b
P2 Progressive infection, persistently p27‑positive †Week 84: multicentric T‑cell lymphomab,c
P3 Regressive infection, provirus‑positive Week 94: feline lower urinary tract disease (FLUTD)
P4 Regressive infection, provirus‑positive Healthy
P5 Regressive infection, provirus‑positive †Week 133: reactivation of infection, multicentric T‑cell 
lymphomab
B R1 Regressive infection, provirus‑positive †Week 26: reactivation of infection, multicentric T‑cell 
lymphoma with secondary lymphoblastic leukemiab
R2 Regressive infection, provirus‑positive Healthy
R3 Regressive infection, provirus‑positive Healthy
R4 Regressive infection, provirus‑positive †Week 28: multicentric T‑cell lymphoma; no reactivation of 
the infection (p27‑negative)b
R5 Regressive infection, provirus‑positive Healthy
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virus isolation assays in cell culture. The two progres-
sively infected cats in group A (cats P1, P2) tested positive 
(Fig.  2), whereas all of the other recipients tested nega-
tive. Moreover, bone marrow was collected 17 weeks post 
transfusion and tested in cell culture in the presence of a 
high dose of hydrocortisone for replicating virus. Latent 
bone marrow infection was detectable in six recipient 
cats: four in group A and two in group B (Fig. 2).
The shedding of FeLV viral RNA was investigated 
using RT-PCR in saliva samples collected at week 0 prior 
to the transfusion and in weeks 3, 5 and 7 post transfu-
sion. Saliva viral RNA was detected in all recipient cats 
in groups A and B with particularly high RNA loads in 
the two cats with progressive infection, P1 and P2 (for 
details, see the table in Additional file 1: Table S1).
Humoral immune response to FeLV
Antibodies to FeLV were detected in plasma samples 
using three different ELISAs (Fig.  3): total anti-FeLV 
(whole virus), anti-p45 (unglycosylated envelope sur-
face protein) and anti-p15E (transmembrane protein). 
All of the recipient cats of groups A and B developed 
antibodies to FeLV to some extent (Figs. 3, 4). The low-
est antibody levels were observed in the two persistently 
infected cats P1 and P2 in group A (Fig. 3). The antibody 
response was earlier and higher in cats in group B than 
in cats in group A: in week 4 after transfusion, four of 
five cats in group B had total anti-FeLV antibody lev-
els >20 % of the positive control, whereas only one of the 
five cats in group A surpassed 20  % in the whole virus 
antibody assay (Fig.  3c, d). Four out of the five cats in 
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Fig. 1 Proviral blood loads (a, b) and plasma viral RNA loads (c, d) of the five cats in group A (a, c) and the five cats in group B (b, d). The proviral 
loads are provided as proviral copies/cell. In the cats in group B, the FeLV provirus was detectable significantly earlier (in week 1) than in the cats 
in group A (pFisher = 0.0079). The cats in group B had significantly higher proviral loads in weeks 1 and 2 but lower loads in weeks 7–12 and 15 
(pMWU < 0.05; indicated by an asterisk). The plasma viral RNA loads are provided as copies/mL of plasma. The cats in group B had significantly higher 
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time points (data not shown)
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group B, but none of the cats in group A, presented anti-
bodies to p15E >60 % of the positive control (Fig. 3g, h; 
pFisher = 0.0476). The cats in group B also exhibited sig-
nificantly higher antibody levels to p15E than the cats in 
group A in weeks 5 and 6 post transfusion (pMWU < 0.05). 
Antibodies to p15E remained low in the two persistently 
viremic cats, P1 and P2. Moreover, in cat P3, only tran-
sient antibodies to p45 were detectable at levels >25 % of 
the positive control (Fig. 3e). At the end of the observa-
tion period at week 15 post transfusion, the two persis-
tently viremic cats in group A (P1 and P2) displayed low 
antibody levels to the whole virus and p15E, whereas all 
of the cats with regressive infection displayed high anti-
body levels (Fig. 3).
To further dissect and confirm the antibody response, 
the samples from all cats collected in weeks 5 and 15 and 
from the blood donor cats collected at the time of the 
blood collection for the transfusion were analyzed by 
western blot (Fig. 4). None of the cats displayed notable 
bands to gp70. Strong bands to p15E were confirmed in 
all cats from groups A and B except for the two persis-
tently viremic cats, P1 and P2. In addition, p15E bands 
in cat P3 became only strong in week 15 after this cat 
had overcome viremia. Only a limited response to p27 
was observed in some cats in groups A and B and in the 
blood donor cat DR at the time of blood collection for the 
transfusion. None of the cats in group C (N1–N5) or the 
donor cat DN presented antibodies to FeLV.
Endogenous FeLV‑like sequences in blood donors 
and recipient cats
Because endogenous FeLV-like sequences can be con-
sidered as a potential confounder in experimental FeLV 
infection, enFeLV provirus loads were determined in 
peripheral blood samples of the 15 recipients and the 
three blood donors collected prior to the blood trans-
fusion using three quantitative PCR assays. The cats in 
group A tended to have somewhat lower enFeLV-env, 
enFeLV-U3-2 and total enFeLV-U3 loads than the cats 
in group B but not to an extent that was statistically sig-
nificant (pMWU enFeLV-env  =  0.0556; pMWU enFeLV-
U3-2  =  0.1508; pMWU total enFeLV-U3  =  0.0952). No 
significant differences were observed when the enFeLV 
loads of the recipients in groups A and B were compared 
with the control cats in group C and blood donor cats 
(PKW > 0.05; for the enFeLV loads, please see the figure in 
Additional file 2: Figure S1).
Cytokine response
To characterize the immune response after the blood 
transfusion and FeLV infection in more detail, the tran-
scription levels of cytokines were determined in EDTA-
anticoagulated blood 0, 1, 2, 3, 11 and 15  weeks after 
the blood transfusion (Fig. 5). To assess a potential Th1 
response, feline interferon-γ (IFN-γ) and interleukin 
(IL-12) were measured. To determine a potential Th2 
response, IL-4, IL-5, IL-6 and IL-10 were also quantified. 
Tumor necrosis factor-α (TNF-α) and IL-6 were assessed 
as pro-inflammatory cytokines, whereas IL-10 exhibits 
anti-inflammatory effects. The most pronounced up-reg-
ulation was observed in IFN-γ levels (Th1) in the cats in 
group B (up to 155-times increase compared with the pre-
transfusion level). The IFN-γ levels changed significantly 
over time for each of the three groups (A: pF = 0.0239; B: 
pF = 0.0053; C: pF < 0.0001), with significantly higher lev-
els in weeks 1 and 15 compared with those in weeks 2, 3 
and 11 (Fig. 5b). Up to a ~20-fold increase was observed 
in IL-5 levels (Th2), with significant changes over time 
for all three groups (A: pF =  0.0239; B: pF =  0.0010; C: 
pF  =  0.0196) and significantly higher levels of IL-5 in 
groups A and B in week 2 compared with those in week 
15 (Fig. 5f ). A significant difference in IL-5 levels among 
the three groups was observed in week 1 (pKW = 0.0004), 
with significantly higher IL-5 levels in group B than in 
group A (pD  <  0.01). Up to 15-fold up-regulation was 
observed for IL-10 (Th2 and anti-inflammatory) com-
pared with the pre-transfusion levels; a significant change 
over time was observed for group A, with significantly 
P1
P2
P3
P4
P5
R1
R2
R3
R4
R5
N1
N2
N3
N4
N5
A
puor
G
B
puor
G
C
puor
G
0   1   2 3   4   5  10 1112 13 14 15    17
Week
negative
positive
Cat 
p27 blood: Virus isolation bone marrow:
negative
positive
Virus isolation blood:
negative
positive
6   7  8  9
†*
†
†  Cat developed FeLV-associated disease
*   Reactivation of infection
†
†
†*
Fig. 2 Outcome of FeLV infection in the recipient cats post transfu‑
sion. Results from p27 ELISA from the blood, virus isolation from the 
blood and virus isolation from the bone marrow of the five cats in 
group A, the five cats in group B and the five cats in the negative con‑
trol group C. Four weeks post transfusion, significantly more cats were 
p27‑positive in group A compared with group B (pFisher = 0.0476)
Page 6 of 18Nesina et al. Retrovirology  (2015) 12:105 
0
10
20
30
40
50
60
70
0 1 2 4 5 6 7 8 9 10 11 12 13 14 15
weeks post transfusion
HBW2
HBZ3
HCC1
HCC4
HCD1
0
p2
7 
(%
 o
f p
os
iti
ve
 c
on
tro
l)
0
10
20
30
40
50
60
70
80
90
100
0
10
20
30
40
50
60
70
80
90
100
p2
7 
(%
 o
f p
os
iti
ve
 c
on
tro
l)
A
nt
i-F
eL
V
 a
bs
 (%
 o
f p
os
iti
ve
 c
on
tro
l)
a
P3
P4
P5
P1
P2
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
R2
R4
R1
R5
R3
b
A
nt
i-F
eL
V
 a
bs
 (%
 o
f p
os
iti
ve
 c
on
tro
l)
weeks post transfusion
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
P3
P4
P5
P1
P2
weeks post transfusion
A
nt
i-p
15
E
 a
bs
 (%
 o
f p
os
iti
ve
 c
on
tro
l)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
HBW2
HBZ3
HCC1
HCC4
HCD1
P3
P4
P5
P1
P2
A
nt
i-p
15
E
 a
bs
 (%
 o
f p
os
iti
ve
 c
on
tro
l)
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
R2
R4
R1
R5
R3
g
weeks post transfusion
c d
A
nt
i-p
45
 a
bs
 (%
 o
f p
os
iti
ve
 c
on
tro
l)
e
* **
* **
0
10
20
30
40
50
60
70
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
0
P3
P
P5
P1
P2
h
A
nt
i-p
45
 a
bs
 (%
 o
f p
os
iti
ve
 c
on
tro
l)
f
0
10
20
30
40
50
60
70
0
10
20
30
40
50
60
70
0
20
40
60
80
100
120
140
160
0
20
40
60
80
100
120
140
160
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
R2
R4
R1
R5
R3
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
R2
R4
R1
R5
R3
0
20
40
60
80
100
120
160
180
140
200
0
20
40
60
80
100
120
160
180
140
200
* *
* *
*
*
Fig. 3 FeLV p27 antigen loads (a, b) and antibodies to FeLV of the five cats in group A (a, c, e, g) and the five cats in group B (b, d, f, h) total anti‑
FeLV antibodies (c, d), anti‑p45 antibodies (e, f) and anti p15E antibodies (g, h). The p27 loads and the antibody levels are provided as percentages 
of a positive control run on each plate. Significant differences between groups A and B are indicated by an asterisk
Page 7 of 18Nesina et al. Retrovirology  (2015) 12:105 
higher levels in week 15 compared with those in week 2 
(pF = 0.0239; pD < 0.05; Fig. 5h). A significant difference 
in IL-10 levels among the three groups was observed in 
week 1 (pKW  =  0.0176), with significantly higher IL-10 
levels in group B compared with group A (pD < 0.05). The 
maximum up-regulation in IL-6 and IL-12 p40 was 8- to 
Fig. 4 Western blot analysis using plasma samples from week 5 and 15 weeks post transfusion. The first five strips were incubated with a positive 
control (pool of immune cats), monoclonal antibodies against gp70, p27 and p15E, respectively, and a negative control (pool FeLV‑negative cats) 
to characterize the respective viral proteins. a Cats N1 to N5, P1 to P3 and DP, DR and DN as indicated. b Cats P4 and P5 and R1 to R5 as indicated. 
Right-pointing triangle denotes bands with expected length. All samples were tested under the same assay conditions
Page 8 of 18Nesina et al. Retrovirology  (2015) 12:105 
1 2 3 1 1 1 5
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
G rou p A
G ro u p B
G ro u p C
1 2 3 1 1 1 5
0
5 0
1 0 0
1 5 0
2 0 0
G rou p A
G ro u p B
G ro u p C
1 2 3 1 1 1 5
0
1
2
3
4
G rou p A
G ro u p B
G ro u p C
1 2 3 1 1 1 5
0
2
4
6
8
0
G rou p A
G ro u p B
G ro u p C
1 2 3 1 1 1 5
0
1
2
3
4
5
G rou p A
G ro u p B
G ro u p C
1 2 3 1 1 1 5
0
5
1 0
1 5
2 0
2 5
G rou p A
G ro u p B
G ro u p C
1 2 3 1 1 1 5
0
2
4
6
8
1 0
G ro u p A
G ro u p B
G ro u p C
1 2 3 1 1 1 5
0
5
1 0
1 5
2 0
G ro u p A
G ro u p B
G ro u p C
C
b
d
a
c
f
h
e
weeks post transfusion weeks post transfusion
IL-12 p35 IL-12 p40
IL-4 IL-5
IL-6 IL-10
*
*
*
* *
ABC
AB
A
AC A C
B
R
el
at
iv
e 
tr
an
sc
rip
tio
n 
le
ve
l
R
el
at
iv
e 
tr
an
sc
rip
tio
n 
le
ve
l
R
el
at
iv
e 
tr
an
sc
rip
tio
n 
le
ve
l
R
el
at
iv
e 
tr
an
sc
rip
tio
n 
le
ve
l
level noitpircsnart evitale
R
level noitpircsnart evitale
R
level noitpircsnart evitale
R
level noitpircsnart evitale
R
g
Fig. 5 Transcription levels of cytokines after blood transfusion in the three groups of cats A, B and C a TNF‑α, b IFN‑γ, c IL‑12 p35, d IL‑12 p40, e IL‑4, 
f IL‑5, g IL‑6 and h IL‑10. The cytokine transcription levels were normalized to the transcription levels of two housekeeping genes (ABL and YWHAZ) 
at each time point and used to calculated relative transcription levels in relation to the levels in week 0 using GeNorm. Significant changes over 
time were tested by the Friedman test for each cytokine and each group, separately; significant differences are indicated by a dotted line; signifi‑
cantly higher (upfilled-pointing triangle) and lower (down-pointing triangle) time points in the Dunn’s posttest (PD) are denoted and the relevant 
group is listed (A, B or C). Significant differences between the three groups at one time point were tested using the Kruskal–Wallis test and are 
indicated by an asterisk
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ninefold, respectively (Fig.  5g, d). A significant change 
over time was observed for IL-12 p40 (Th1) in group C 
(pF  =  0.0055), with higher levels in week 11 compared 
with those in weeks 1 and 15 (pD < 0.05); in week 11, a 
significant difference was observed among the three 
groups in IL-12 p40 levels (pKW = 0.0273). For IL-6 (Th2 
and pro-inflammatory), a significant change over time 
was observed for group B (pF = 0.0244) but lost signifi-
cance in the posttests. Significant changes over time were 
also observed for IL-4 (Th2) for groups A (pF = 0.0085) 
and C (pF = 0.0031), with significantly higher IL-4 levels 
in week 2 compared with week 1 for group A and sig-
nificantly higher levels in week 11 compared with week 
1 for group C (both pD  <  0.05; Fig.  5e). Significant dif-
ferences among the groups were observed in week 1 
(pKW =  0.0440) and week 11 (pKW =  0.0391), with sig-
nificantly lower levels of IL-4 in group A compared with 
those in group B at both time points (pD  <  0.05). No 
significant differences between the three groups and no 
significant changes over time were observed in the IL-12 
p35 transcription levels (Fig. 5c), and only minor up-reg-
ulation was observed for TNF-α (up to 2.3-fold; Fig. 5a).
Clinical and laboratory findings
For 15  weeks post transfusion, weekly clinical exami-
nations were performed by veterinarians. Two cats in 
group A (viremic P2 and P3) and one cat in group B (R1) 
exhibited elevated body temperatures after transfusion of 
39.8 °C in week 6, 40.1 °C in week 8 and 39.6 °C in week 
3, respectively. The two cats in group A presented with 
anorexia and mild lethargy during these episodes; after 2 
days of treatment with meloxicam and intravenous fluids, 
the two cats recovered. Lymphadenomegaly of the man-
dibular, cervicalis superficialis and popliteal lymph nodes 
was observed in all five cats in group A and four of the 
five cats in group B. The lymphadenomegaly was more 
distinct and persistent in the cats in group A than in 
group B. None of the cats in group C developed elevated 
body temperatures or lymphadenomegaly (for additional 
details, please see the table in Additional file 3: Table S2).
A complete hematological was performed from EDTA-
anticoagulated blood samples collected from all recipient 
cats prior to the blood transfusion and weekly thereafter 
until week 15. In addition, clinical chemistry was performed 
from sera at week 0 and at the appearance of clinical signs. In 
accordance with increasing age of the cats, the median PCV 
of the cats in groups B and C significantly increased between 
5 and 6 % over time (B: pF = 0.0002, week 2–15 pD = 0.0354; 
C: pF = 0.0003, week 0–15 pD = 0.0402; see also Additional 
file 4: Figure S2). A decrease in PCV was observed in several 
cats in group A at the onset of antigenemia approximately 
at weeks 4–5 post transfusion. This decrease resulted in 
significantly lower PCV in group A compared with group C 
7 weeks post transfusion (pMWU = 0.0317).
The white blood cell (WBC) counts significantly 
changed over time in group B (pF = 0.0008); following a 
severe decrease in the WBC counts in all cats between 
weeks 0 and 2 (lowest value observed: 5.9 × 103/μL; ref-
erence range at this age 23.2 ± 3.36 × 103/μL, [34]), a sig-
nificant rebound was observed (week 2–6; pD = 0.0184; 
see also Additional file 5: Figure S3). The slowest recov-
ery of WBC counts was observed in cat R4, which also 
overcame antigenemia at the latest time point within 
group B. This temporary decrease resulted in signifi-
cantly lower WBC counts in the cats in group B com-
pared with those in the cats in the control group C in 
week 2 (pMWU = 0.0397). In group A, WBC counts also 
decreased post transfusion but not in all cats simultane-
ously. In the transiently antigenemic cats P4 and P5, a 
rebound of WBC counts was observed starting in weeks 
5–6, whereas only a limited and late increase in WBC 
counts (starting in week 9) was observed in the two cats 
with progressive infection, P1 and P2.
In neutrophil granulocyte counts, a significant change 
over time was observed for group A (pF  =  0.0163) but 
lost significance in the posttests (data not shown). The 
lowest neutrophil counts and severe intermittent neutro-
penia were observed in the persistently infected cat P2, 
with counts as low as 0.2  ×  103/µL (reference range at 
this age 11.0 ± 1.77 × 103/μL, [34]).
Significant changes over time were observed in the 
lymphocyte counts in group B (pF =  0.0013) but not in 
groups A or C (see also Additional file 6: Figure S4). All 
of the cats in group B exhibited a decrease in lympho-
cyte counts from weeks 0–1 post transfusion. A similar 
decrease was also observed 1 week later in the cats P3, 
P4, P5 in group A (week 1–2)—these three cats all over-
came antigenemia similar to the cats in group B.
In weeks 8 and 9 post transfusion, moderate hyperpro-
teinemia and moderate hypoalbuminemia were detected 
in cat P3 in group A immediately after the cat had over-
come antigenemia (Fig. 2) and had developed high levels 
of antibodies to FeLV (Fig.  3c). Serum protein electro-
phoresis revealed moderate hyperbetaglobulinemia and 
severe polyclonal hypergammaglobulinemia, compatible 
with chronic immune stimulation (data not shown).
Long‑term follow up and clinical outcome of the recipient 
cats
After the initial observation period of 15 weeks after the 
blood transfusion, all cats remained in the facility, were 
regularly examined, and hematology, blood chemistry 
and p27 analyses were performed routinely until week 
149.
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In week 26 post transfusion, the cat R1 in group B 
developed a reactivation of the FeLV infection with 
p27 blood levels of 113  % (see also [23]) and had to be 
euthanized due to severe dyspnea (Table  1). Upon nec-
ropsy, a multicentric lymphoma of the thymus, the 
mesenteric lymph node, the liver and the bone mar-
row was observed with secondary lymphoblastic leuke-
mia (WBC = 49 × 103 cells/µL; 75 % lymphoblasts; see 
also Additional file  7: Figure S5). Histopathological and 
immunohistological examination revealed a T-cell lym-
phoma (CD3+ CD79a−).
In week 28 post transfusion, the cat R4 in group B was 
euthanized because of pleural effusion. Upon necropsy, 
a multicentric T-cell lymphoma (CD3+ CD79a−) of the 
thymus, kidney and lumbar lymph node was observed 
(Table  1). The cat tested p27-negative at the time of 
death.
In week 31, the persistently infected cat P1 in group 
A had to be euthanized because of severe normocytic-
normochromic non-regenerative anemia and moderate 
leukopenia due to moderate neutropenia. At the time 
of euthanasia, the p27 antigen load was 114 %. FeLV-C, 
which is typically associated with the development of 
non-regenerative anemia in FeLV-infected cats [7], was 
detectable by subgroup PCR (see also Additional file  8: 
Figure S6). In addition, FeLV-B was detected, which 
arises in many cats with FeLV-A infection [3].
In week 84, the persistently viremic cat P2 had to be 
euthanized because of severe dyspnea caused by pleural 
effusion when the cat was vaccinated but not re-exposed 
to FeLV (listed as BZ3 in [35]) in a follow-up study. 
Cytological examination of the pleural effusion revealed 
numerous lymphatic blasts with a total nucleated cell 
count of 40.53 × 103/µL. Additionally, the cat exhibited 
moderate lymphopenia, moderate hypoproteinemia, 
moderately increased alkaline phosphatase activity and 
slight hypochloremia. The p27-value in this cat increased 
in 4 weeks from 75 to 174 %. Necropsy revealed a multi-
centric T-cell lymphoma (CD3+ CD79a−) in the thymus, 
pericardium, tonsils and prescapular lymph nodes.
The cat P3 in group A, which exhibited hyperproteine-
mia and polyclonal hypergammaglobulinemia 8 weeks 
after infection, subsequently developed feline lower uri-
nary tract disease (FLUTD) 94  weeks after transfusion 
and had to undergo intensive care outside of the barrier 
facility in the Small Animal Clinic at the Vetsuisse Fac-
ulty; the cat was placed privately after complete recovery.
In week 133 post transfusion, the cat P5 in group A 
had to be euthanized due to clinical deterioration (per-
sistent anorexia, apathy). The cat exhibited anisocoria in 
week 131 and tested p27-positive (11 %), indicating reac-
tivation of the infection. The p27 value increased subse-
quently to 27  % at the time of euthanasia. The samples 
collected prior to euthanasia were all viral RNA-positive. 
Upon necropsy, a multicentric T-cell lymphoma (CD3+ 
CD79a−) of the thymus and liver was observed (Table 1).
The remaining four of ten FeLV exposed recipient cats 
and all control cats in group C remained healthy to the 
time point of writing this manuscript (149  weeks after 
blood transfusion).
Long‑term follow up and clinical outcome of the blood 
donor cats
The blood donor cat for group B, cat DR, but not for 
group A, cat DP, was confirmed latently FeLV infected 
judged from bone marrow cell culture (in the presence of 
high doses of hydrocortisone) 18  weeks after the blood 
collection for the blood transfusion and 60  weeks after 
experimental FeLV exposure. At this time point, the cat 
DR demonstrated a reactivation of the FeLV infection 
with a p27 blood level of 132  % (see also [23] listed as 
GCN4). Clinically, the cat exhibited severe dyspnea and 
pleural effusion. Upon necropsy, a multicentric T-cell 
lymphoma (CD3+ CD79a−) of the thymus and inguinal 
lymph node was identified (Table  1). The blood donor 
for group A, cat DP, remained p27-negative and clinically 
healthy until 149  weeks after blood collection for the 
transfusion and 191 weeks after FeLV exposure.
Discussion
Our results demonstrate for the first time that FeLV 
infection can be transmitted to naïve recipients via the 
transfusion of blood from a FeLV provirus carrier. Blood 
was collected for the transfusion 42 weeks after the blood 
donors had been exposed to FeLV and contained a low 
provirus load. Approximately 104 provirus copies within 
10 mL of blood were sufficient to result in a productive 
FeLV infection in all recipients. Young cats were selected 
for this experiment because they are more suscepti-
ble to FeLV infection than adult cats [36]. Although this 
increased susceptibility in young cats may be because 
of immaturity of the immune system, increased suscep-
tibility to FeLV may also be expected in blood transfu-
sion recipients because of severe clinical conditions and/
or possible immunosuppression. Moreover, the trans-
fused volume, 10 mL, was adjusted to the body weight of 
the kittens (~1–1.5 kg at the time of the transfusion) to 
reflect the volume of a regular blood transfusion in adult 
cats (usually 40–60 mL for a cat of ~4 kg body weight). 
Thus, the chosen experimental setup may well mirror the 
situation in the field for adult blood transfusion recipi-
ents. Some of the recipient cats subsequently developed 
FeLV-associated disease, confirming our hypothesis 
that whole blood containing white blood cells carrying 
FeLV provirus will transfer the virus and result in full-
blown infection in recipient cats. Our results confirm 
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and extend previous results in which FeLV infection was 
transmitted by subcutaneous injection of a plasmid car-
rying the proviral DNA [33]. Additionally, productive 
infection after intramuscular or intradermal injection of 
plasmids carrying proviral DNA were reported for the 
feline immunodeficiency virus in cats [37, 38] and the 
simian immunodeficiency virus in macaques [39]. Our 
study provides direct biological relevance and clinical 
importance: we conclude that there is an imminent risk 
of FeLV transmission via blood transfusion of provirus-
positive blood, which must be considered in the clinic. 
By performing the commonly used blood donor screen-
ing assay (detecting the p27 antigen), both of the FeLV-
infected blood donors that were used in the current study 
would not have been recognized as a risk. Therefore, we 
highly recommend screening all feline blood donors and 
blood products not only for FeLV antigen but also for 
FeLV provirus using sensitive PCR.
The provirus in the peripheral blood of the blood 
donors was replication-competent  ~10  months after 
the initial virus exposure; however, viral replication was 
suppressed by the blood donors’ immune system to 
undetectable levels. When the cells containing the pro-
virus entered a new susceptible host via blood trans-
fusion, viral replication reignited. We were unable to 
determine from our data whether this reigniting was 
primarily because of the absence of a prepared immune 
system in the recipient cat or also because of a mixed 
lymphocyte-type reaction resulting in blastogenesis in 
the donor lymphocytes and FeLV expression contribut-
ing to the fast onset of viral replication. Such a reaction 
would be expected to occur within hours to a few days 
after the blood transfusion; no blood samples were col-
lected at these time points, e.g., for lymphocyte isola-
tion, flow cytometry analysis of lymphocyte populations 
or cytokine measurements. One week after transfusion 
(the earliest time point analyzed), an increase in total 
lymphocyte numbers was observed only in some cats in 
groups A and C; by contrast, all cats in group B exhibited 
a decrease in lymphocyte counts, which does not support 
the hypothesis of a mixed lymphocyte reaction. There-
fore, if one assumes that FeLV was actively suppressed 
in the blood donors by the immune system but not in 
the recipients, the immune mechanism predominantly 
involved in the control of FeLV replication was not or was 
insufficiently transferable via blood transfusion. The lat-
ter would be true for the cellular immune response; it has 
been demonstrated previously that the cellular immune 
response plays an important role in suppressing viral rep-
lication in FeLV infections [40].
The replication competence of the provirus was fur-
ther corroborated when one of the FeLV-exposed 
blood donors (DR) presented with a reactivation of the 
infection and the development of a multicentric lym-
phoma 4 months after the blood collection or the trans-
fusion. The second provirus-positive cat serving as the 
blood donor for group A (cat DP) remained healthy and 
clinically unremarkable 149 weeks after the initiation of 
this study, although its blood had resulted in progressive 
infection in two recipient cats and FeLV-associated fatal 
disease in three recipients. Cat DP remains provirus-pos-
itive with a low provirus load. Further studies will be nec-
essary to analyze the immune response in this and other 
provirus-positive long-term survivors that successfully 
keep the replication competent virus in check.
The FeLV infection that was observed in cats in groups 
A and B resembled a natural FeLV infection in regards to 
clinical findings, laboratory changes, infection outcome, 
disease spectrum and FeLV subgroup evolvement. The 
infected cats exhibited elevated body temperatures, lym-
phadenomegaly, anorexia, lethargy and changes in hema-
tological parameters, including anemia and neutropenia. 
The severity of the clinical signs was associated with the 
severity of the infection: the lymphadenomegaly was par-
ticularly pronounced in the two viremic cats in group A, 
P1 and P2. Natural FeLV infection is characterized by 
leukopenia, lymphopenia and variable degrees of anemia 
[1]. A decrease in the WBC and lymphocyte counts was 
also observed in the present study in the FeLV-exposed 
cats but not in the control cats. The decrease in WBC 
and to some degree in lymphocyte counts appeared to 
be directly associated with the initial FeLV infection 
and the onset of viral replication; furthermore, the cats 
that recovered quickly from antigenemia exhibited a fast 
rebound of WBC counts. In addition, the cats in group A 
did not exhibit an adequate increase in PCV as observed 
in the control cats and related to the increasing age of the 
cats [34].
Replicating viruses were detected by cell culture in 
the blood or the bone marrow (the latter in the presence 
of high doses of hydrocortisone) in six recipient cats in 
groups A and B, confirming the replication capacity of 
FeLV in these six cats after infection via blood transfu-
sion containing proviral DNA ± viral RNA. In addition, 
all eight of the recipient cats with regressive infection 
developed antibodies to FeLV, indicating the presence of 
at least minimal viral replication in these cats. By con-
trast, persistently infected cats exhibited lower antibody 
levels, as has been previously described in natural and 
experimental FeLV infected cats [19, 41]. Incidentally, 
no antibodies to gp70 were detectable in any of the cats 
by western blot. The virus preparation used for the blots 
were produced on FL-74 cells that harbor FeLV-ABC, 
but mainly C, for practical reasons (considerably higher 
yield), whereas the cats of the present study had been 
exposed to FeLV-A. gp70 but not p27 of FeLV-A and –C 
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exhibited antigenetic differences. Moreover, gp70 may 
also be denatured during the antigen preparation (boil-
ing in SDS), potentially resulting in loss of the three-
dimensional structure and a lack of antibody binding. No 
samples were available for virus neutralization assays in 
the present study. Consistent with earlier data [41], only 
a few cats with regressive infection developed antibodies 
to p27. It is quite unlikely that these antibodies interfered 
with the detection of the p27 antigen in these cats; sera 
containing strong antibody reactivity to FeLV p27 did not 
interfere with antigen detection supposedly because of 
the high affinity of the anti-p27 monoclonal antibodies 
used in the p27 ELISA [42]. Subsequently, five of the ten 
recipient cats succumbed to FeLV-associated diseases. 
The cats suffered from non-regenerative anemia, T-cell 
lymphoma and leukemia, which are commonly regarded 
as FeLV-associated diseases [1]. Finally, the appearance 
of non-regenerative anemia was associated with the 
emergence of FeLV-C. This result also parallels natural 
FeLV-infection, in which the development of FeLV-C 
from FeLV-A via mutations has been described for FeLV-
infected cats suffering from non-regenerative anemia [3, 
43].
The cats that received blood containing only provi-
ral DNA (group A) exhibited a later onset but graver 
outcome of FeLV infection compared with the cats that 
were transfused with blood containing not only proviral 
DNA but also viral RNA (group B). Initially, the cats in 
group B became provirus-positive significantly earlier 
after transfusion and developed significantly higher viral 
RNA and proviral loads than did the cats in group A. 
However, several weeks after the transfusion, the cats in 
group A exhibited significantly higher viral RNA, proviral 
and p27 antigen loads compared with those in group B. 
Moreover, more cats in group A were p27 antigen-posi-
tive compared with those in group B, two cats in group A 
but none in group B developed persistent infection, and 
some cats in group B but none in group A became viral 
RNA-negative within the observation period. A possible 
explanation for these observations could be the more 
efficient detection of FeLV by the immune system of cats 
in group B because of the presence of viral RNA and the 
higher proviral DNA loads in the transfused blood com-
pared with those in group A. In group A, only low loads 
of provirus hidden within the donor cells were present. 
The differences in viral loads were paralleled by varia-
tions in the leukogram: a marked decrease in WBC and 
lymphocyte counts was observed in the cats in group 
B in week 1 when those cats, but not those of group A, 
tested viral RNA positive. Moreover, 1 week post trans-
fusion in all cats, but particularly in the cats in group B, 
high IFN-ɣ levels with a maximum ~ 150-times increase 
were observed. IFN-γ plays a critical role in the innate 
and adaptive immunity against viral infections, partially 
through direct inhibitory effects on viral replication but 
primarily by immune stimulatory and modulatory effects 
on cellular defense mechanisms [44]. In FeLV-specific 
immunity, an important role of specific cytotoxic T lym-
phocytes was demonstrated, and FeLV-specific effec-
tor cytotoxic T-cell responses were detected as early as 
1 week after virus exposure and were over the course of 
the early infection particularly high in cats that recov-
ered from viremia [40]. Furthermore, the cats in group 
B exhibited higher IL-4, IL-5 and IL-10 levels compared 
with those in group A in week 1 after the transfusion; 
however, the changes in these cytokines were much 
less pronounced than in IFN-ɣ. IL-4 is a key regulator 
of humoral immunity and promotes the differentiation 
of Th2 cells, whereas IL-5 is produced by Th2 cells and 
stimulates B cells and antibody secretion. IL-4 and IL-5 
levels increased in the cats in group A in week 2. Mod-
erately increased levels of IL-10 were observed in group 
B around week 2 or 3, whereas in group A, these levels 
were detected only in weeks 11 and 15. IL-10 has multi-
ple effects but is also associated with B cell proliferation 
and antibody production. Accordingly, more cats with 
high anti-FeLV antibody levels were observed in group 
B than in group A 4–6 weeks after virus exposure. Alto-
gether, the data indicate that the immune systems of the 
cats in group B reacted quicker and more pronounced to 
the transfused blood and the virus that was transmitted 
with the blood compared with the cats in group A. This 
result supports our assumption of more efficient detec-
tion of FeLV by the recipients of the blood from blood 
donor B, in which viral RNA and higher proviral loads 
were present.
An additional factor resulting in differences in viral 
loads after FeLV exposure may have been the loads in 
enFeLV, which are present in each cell of the cat but with 
inter-individual differences. An association between 
enFeLV loads and FeLV replication has been reported 
previously: cats with high enFeLV loads exhibited higher 
viral replication than cats with low enFeLV loads in the 
early phase of a persistent FeLV infection [45]. Moreover, 
low enFeLV loads prior to FeLV exposure may be signifi-
cantly associated with the development of a progressive 
infection, whereas cats with high enFeLV loads may 
rather develop a regressive infection [45, 46]. The cats in 
the present study originated all from the same SPF cat-
tery, and the recipient cats were assigned into the three 
groups to avoid familial clustering. Nonetheless, the cats 
in group A tended to have somewhat lower enFeLV loads 
than the cats in group B, which would, as outlined above, 
fit to the lower FeLV replication observed early during 
infection and the higher number of cats who developed 
progressive infection in group A compared with group B.
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A reactivation of FeLV infection was observed in three 
cats in the present study—one blood donor (cat DR, 
donor for group B) and two recipient cats (R1, group B 
and P5, group A)—further emphasizing the biological 
and epidemiological importance of provirus-positive cats 
and supporting our recommendation to test cats that are 
suspected to have been exposed to FeLV by PCR to iden-
tify FeLV provirus carriers. Subsequent to reactivation, 
provirus positive cats pose an infection risk to naïve cats. 
In addition, in our hands, all of the cats with reactivated 
infection developed fatal FeLV-associated disease [11, 
22, 23]. Thus, to detect provirus carriers, e.g., to further 
decrease FeLV incidence in a feline population, cats with 
exposure risk should not only be tested for FeLV anti-
genemia/viremia but also for FeLV provirus. Plasma viral 
RNA could also be detected in the recipient cats R1 and 
P5 prior to reactivation, further supporting our hypoth-
esis that the presence of plasma viral RNA may be associ-
ated with a higher probability of reactivation of the FeLV 
infection [11, 12]. Therefore, the detection of plasma viral 
RNA in provirus positive aviremic cats may serve as a 
marker for potential reactivation.
The recipient cats shed viral RNA in their saliva at var-
ying degrees post transfusion. A high load of saliva viral 
RNA was primarily noted in the viremic cats, but FeLV 
RNA was also observed in cats with regressive infec-
tion, confirming a previous observation that during early 
infection, saliva viral RNA may not be a good marker for 
antigenemia/viremia [26], in contrast with long-term 
infected cats [28].
Conclusions
Since the introduction of sensitive molecular methods, 
the occurrence of cats with FeLV proviral DNA in the 
absence of antigenemia and viremia has been well docu-
mented [10, 12, 19]. Up to 10 % of provirus-positive cats 
have been described among the Swiss cat population 
[19]. The results of our study underline the biological and 
epidemiological relevance of retroviral provirus in FeLV 
aviremic cats, further supporting observations that the 
proviral DNA in cats with regressive infection may main-
tain its replication capacity for many months to years 
[22, 23]. Sensitive PCR is recommended to detect provi-
rus carriers as demonstrated in the current study to be 
performed in any cat serving as a blood donor to exclude 
inadvertent transmission of FeLV to the blood recipients 
but also in general to further decrease the incidence of 
FeLV infection within the cat population. The FeLV vac-
cines that are currently available can be efficacious in 
preventing persistent infection and the development of 
diseases subsequent to virus exposure; however, these 
vaccines do not prevent provirus integration [21]. Ideally, 
in the future, vaccines will be developed that also prevent 
provirus integration. Moreover, viral eradication treat-
ments should be developed that eliminate proviral DNA 
in infected hosts. The latter is also a goal envisioned for 
HIV in humans [47, 48].
Methods
Animals
A total of 18 SPF cats (Liberty Research, Waverly, NY, 
USA) were included in this study: three adult male cas-
trated SPF cats served as blood donors, and 15 eight-
week-old-male SPF kittens served as blood transfusion 
recipients (Table  1). The recipient cats were randomly 
assigned to three groups of five cats each, avoiding famil-
ial clustering. Group A comprised cats P1–P5 (original 
cat IDs HBW2, HBZ3, HCC1, HCC4, and HCD1). Group 
B comprised cats R1–R5 (original cat IDs HBU1, HBW1, 
HBZ1, HCC3, and HBY1). Group C comprised cats N1–
N5 (original cat IDs HBU2, HBV1, HBZ2, HCC2, and 
HCD2). Two of the three adult blood donors, DP and DR 
(original cat IDs GBX3, GCN4), had been experimentally 
exposed to FeLV-A/Glasgow-1 as previously described 
(listed as BX3 and CN4 in the previous study, [46]). These 
cats had undergone a regressive infection with undetect-
able antigenemia at the tested time points; the blood for 
the transfusion was collected 42  weeks after the infec-
tion. The third blood donor, DN (original cat ID GCN5), 
was a naïve adult SPF cat.
All cats were maintained in separated groups in a con-
fined university facility under barrier conditions and 
optimal ethological and hygienic conditions as previously 
described [49]. All experiments were performed accord-
ing to Swiss law and officially approved by the veterinary 
office of the canton of Zurich (160/2010, 129/2010). Prior 
to the start of the experiment, each cat was clinically 
examined, and blood and plasma samples and conjunc-
tival, oropharyngeal, and rectal swabs were collected to 
verify the cats’ SPF status. These samples were tested for 
absence of FeLV, feline immunodeficiency virus, hemo-
plasmas, parvovirus, calicivirus, herpesvirus 1, corona-
virus, Bartonella henselae, and Chlamydophila felis, as 
previously described [50]. In addition, the serum sam-
ples were tested for antibodies against feline calicivirus, 
feline herpesvirus and feline parvovirus by immunofluo-
rescence assays as previously described [51]. All of the 
cats were negative for all of the tested infections. Upon 
arrival, the kittens were adapted to the new environment 
and the care persons for 2 weeks and trained for relaxed 
handling and blood collections without anesthesia.
Experimental design and blood transfusion
For blood transfusion, 50 mL of blood was collected from 
each of the three adult blood donors—DP, DR and DN—
under intramuscular anesthesia (10  mg/kg ketamine, 
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Narketan®, Vétoquinol AG, Belp, Switzerland; 0.1  mg/
kg midazolam, Dormicum®, Roche Pharma AG, Reinach, 
Switzerland). The blood was collected in a syringe con-
taining 7 mL of the anticoagulant citrate phosphate dex-
trose adenine (CPDA-1, Fenwal, Lake Zurich, IL, USA). 
The blood from each donor was divided into five syringes 
of 10 mL—one syringe per recipient cat. The donor cats 
were administered 50  mL of Ringer-Lactate solution 
(Fresenius Kabi, Stans, Switzerland) and monitored until 
recovery from anesthesia.
The 15 kittens each received 10  mL of anti-coagu-
lated whole blood at the age of 10 weeks. The blood for 
the cats P1–P5 in group A was FeLV provirus-positive 
(1 × 103 copies/mL of blood) and plasma viral RNA- and 
p27-negative (donor DP). The blood for cats R1–R5 was 
provirus- (6.25  ×  103 copies/mL of blood) and plasma 
viral RNA-positive (1.95 × 105 copies/mL of plasma) and 
p27-negative (donor DR). The blood for cats N1–N5 was 
FeLV provirus-, viral RNA- and p27-negative (donor DN). 
Prior to the transfusion, the blood types of each donor 
and recipient cat were determined using a commercial 
immunochromatographic test (Lab Test A + B, Alvedia, 
France). Moreover, a standard saline-agglutination cross-
matching procedure was performed at 37 °C with blood 
from the recipients and the corresponding blood donors 
[52]. All of the cats were of blood type A, and the recipi-
ent cats were compatible with the donors in the cross-
match. The kittens were anesthetized intramuscularly as 
described above, and 10 mL of whole blood was collected 
for baseline analysis and to prevent circulatory volume 
overload. Thereafter, 10 mL of blood from the respective 
blood donor was transfused slowly over 30 min to each 
recipient cat. During and after the blood transfusion, the 
kittens were monitored for adverse reactions. The general 
conditions of the cats were monitored daily. The recipient 
cats were castrated 24 weeks after transfusion.
Hematology, clinical chemistry and serum protein 
electrophoresis
WBC counts and complete hemograms were per-
formed using a Sysmex XT-2000iV (Sysmex Corpora-
tion, Kobe, Japan) [53]. Blood smears were stained using 
an automated staining instrument (HemaTek, Siemens, 
Switzerland), and differential counts were performed 
microscopically. In the case of severe anemia, manual 
reticulocyte counts were performed using a stand-
ard method based on Brilliant Cresyl Blue- (SIGMA-
ALDRICH, Steinheim, Germany) stained blood smears. 
Clinical chemistry was analyzed using a Cobas Integra 
800 system (Roche Diagnostics, Rotkreuz, Switzerland) 
at week 0 and at the appearance of clinical signs. Serum 
biochemistry analysis included bilirubin, glucose, blood 
urea nitrogen, creatinine, protein, albumin, cholesterol, 
alkaline phosphatase, aspartate aminotransferase, ala-
nine aminotransferase, lipase, sodium, chloride, potas-
sium, phosphorus and calcium levels. Serum protein 
electrophoresis was performed in one cat with hyper-
proteinemia in week 8 and 9 (cat P3, group A) using a 
semi-automated agarose gel electrophoresis system as 
previously described [54].
Nucleic acid extractions, complementary DNA synthesis 
and quantification of FeLV proviral and viral RNA loads
To determine proviral loads, DNA was extracted from 
100 µL of buffy coat obtained from 1 mL of EDTA-anti-
coagulated blood using the QIAamp Blood Kit (Qiagen, 
Hombrechtikon, Switzerland) and 100 µL of elution 
buffer. To determine plasma viral RNA loads, total 
nucleic acid (TNA) was extracted from 200 µL of EDTA 
plasma using the MagNA Pure LC Total Nucleic Acid 
Isolation Kit (Roche Diagnostics) and 100 µL of elution 
buffer. To determine the viral RNA loads in the saliva, the 
swabs were processed using 200  μL of phosphate-buff-
ered saline as previously described [28]. To determine 
the cytokine transcription levels, 100 μL of EDTA-anti-
coagulated blood was mixed immediately after blood 
collection with 300 μL mRNA lysis buffer (mRNA Isola-
tion Kit I, Roche Diagnostics) and frozen as previously 
described [55]. mRNA was purified using the mRNA 
Isolation Kit I on a MagNA Pure LC instrument (Roche 
Diagnostics) and 25 µL of elution buffer [55]. First-strand 
complementary DNA (cDNA) was synthesized using the 
High-Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Rotkreuz, Switzerland) in duplicate from 
each sample. In all of the extractions, negative controls 
consisting of phosphate buffered saline were extracted in 
parallel to monitor for cross-contamination.
FeLV provirus loads were quantified by TaqMan PCR 
targeting the unique region U3 of the long terminal 
repeat of FeLV as previously described [56] using 5 μl of 
TNA and the TaqMan Fast Universal PCR Master Mix 
(Applied Biosystems). This assay amplifies the three FeLV 
subgroups A, B, and C, but not enFeLV. The lower limit 
of detection of this assay is one provirus copy per reac-
tion [56]. The thermocycling conditions were as follows: 
an initial denaturation of 20  s at 95  °C, followed by 45 
cycles of 95 °C for 3 s and 60 °C for 45 s. Provirus loads 
were normalized to feline albumin copy numbers using 
TaqMan PCR as previously described [57]. The number 
of FeLV proviral copies in 10 mL of transfused blood was 
calculated using the extraction, elution and PCR volumes 
and the copies/PCR measured by PCR. TNA from plasma 
and saliva was analyzed by TaqMan RT-PCR targeting 
the same U3 region as the provirus PCR as previously 
described [56],using 5  μl of TNA and the SuperScript™ 
III Platinum® One-Step Quantitative RT-PCR System 
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(Invitrogen, Basel, Switzerland). The lower limit of detec-
tion of this assay is 180 viral RNA copies per reaction 
[56]. Plasma viral RNA loads were calculated as the num-
ber of copies per milliliter of blood. The number of viral 
RNA copies in 10 mL of transfused blood was calculated 
using the PCV and the number of copies/mL of plasma 
that was determined by RT-PCR. All of the PCR and RT-
PCR assays were run on an ABI 7500 FAST Real-Time 
PCR System (Applied Biosystems); negative, positive and 
extraction controls were included in each run.
Quantification of endogenous FeLV‑like proviral loads
enFeLV provirus loads were determined in peripheral 
blood samples collected prior to the blood transfusion 
using quantitative real-time TaqMan PCR assays on an 
ABI 7500 FAST Real-Time PCR System (Applied Bio-
systems) as previously described [45, 58]. The following 
enFeLV targets were measured: enFeLV-U3-1, enFeLV-
U3-2 and enFeLV-env. Total enFeLV-U3 copy numbers 
were calculated by addition of the enFeLV-U3-1 and 
enFeLV-U3-2 copy numbers. Provirus loads were nor-
malized to feline albumin copy numbers using TaqMan 
PCR as previously described [57].
Serological assays
EDTA-anticoagulated plasma samples were analyzed for 
the presence of p27 by double-antibody sandwich ELISA 
using monoclonal antibodies to three epitopic regions of 
p27 as previously described [59]. Antibodies to the FeLV 
whole virus were determined by ELISA [19, 21] using 
0.2  µg FeLV per well purified by sucrose gradient from 
cell culture supernatant from FL-74 cells chronically 
infected with FeLV as previously described [41, 60]. Anti-
bodies to the recombinant p15E transmembrane pro-
tein (25  μg/well) and the recombinant non-glycosylated 
form of the gp70 surface glycoprotein (p45; 0.2 μg/well) 
were measured by ELISA as previously described [61, 
62]. The results were calculated as the percentages of 
a defined positive control run with each test; samples 
reaching >4 % of the positive control were considered to 
be positive in the p27 ELISA [19]. In addition, antibod-
ies to FeLV were determined by western blotting using 
20 μg of FeLV per blot purified by sucrose gradient from 
FL-74 cell culture supernatant as previously described 
[60]. EDTA-anticoagulated plasma samples were diluted 
1:200 and the peroxidase conjugated goat-anti-cat anti-
bodies (Jackson ImmunoResearch Laboratories, Inc., 
PA) were diluted 1:1000. Primary in-house monoclo-
nal mouse ascites antibodies to gp70, p27, p15E [59, 63] 
diluted 1:400 and a secondary peroxidase conjugated 
goat-anti-mouse antibody (Jackson ImmunoResearch 
Laboratories) at a dilution of 1:1000 were used as positive 
controls. Moreover, pooled EDTA plasma samples from 
immune and SPF cats were used as positive and negative 
controls, respectively.
No serological analysis was possible because of lack of 
sample volume in week 3. No heparin plasma samples 
were available to test FeLV neutralizing activity in the 
donor or recipient cats.
Virus isolation from peripheral blood and bone marrow
For virus isolation from peripheral blood, lithium hep-
arin-anticoagulated samples were collected from the 
recipients 5 weeks post transfusion. Virus isolation was 
performed using 200 µL of lithium heparin plasma and 
QN10S cells as previously described [64]. The cells were 
monitored daily for cytopathic effects; at day 7, cell cul-
ture supernatant was collected for the quantification of 
the p27 antigen by ELISA.
For the detection of latent infection [16], bone marrow 
aspirates were collected from the proximal humerus from 
the recipient cats 17  weeks post transfusion and from 
the blood donors 18 weeks after the blood collection for 
transfusion (60 weeks into infection) under general anes-
thesia and analgesia as previously described [50]. The 
bone marrow was collected in 3.5 mL of RPMI 1640 cell 
culture medium (SIGMA-ALDRICH, Buchs, Switzer-
land) with 200  mM  L-glutamine, 400 U/mL penicillin, 
400 µg/mL streptomycin (Invitrogen) and 10 % FCS (Bio-
Concept,  Allschwil, Switzerland). Crandell feline kidney 
(CrFK) cells (20,000 cells/mL) were cultured in a 24-well 
plate (TPP Techno Plastic Products AG,  Trasadingen, 
Switzerland) to 75  % confluence. These cells were con-
firmed to be FeLV-negative by PCR. The bone marrow 
cells were resuspended in medium and co-cultured with 
the CrFK cells. The cells with medium only were concur-
rently cultured on each plate. The cell culture medium 
contained the following: RPMI and Mc Coys 5A (1:1; 
SIGMA-ALDRICH), 200  mM  L-glutamine, 400 U/mL 
penicillin, 400 µg/mL streptomycin, 10 % FCS and 1 µg/
mL hydrocortisone (SIGMA-ALDRICH). The cultures 
were maintained for 12  weeks, and half of the medium 
was replaced every 3rd day, when the supernatant was 
collected for p27 ELISA and FeLV RT-PCR.
Detection of FeLV subgroups
The development of non-regenerative anemia in FeLV-
infected cats is typically associated with the emergence 
of FeLV-C [7]. Therefore, in one cat (P1) that had to be 
euthanized with non-regenerative anemia, the FeLV sub-
groups were investigated in the blood plasma and bone 
marrow, both of which were collected at the time of nec-
ropsy. The FeLV-A-specific primers RB59 and RB17, the 
FeLV-B-specific primers RB53 and RB17 and the FeLV-C-
specific primers RB58 and RB47 were used in a conven-
tional PCR as previously described [22, 65, 66].
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Cytokine transcription
To quantify cytokine levels in the peripheral blood, 
real-time PCR and primers and probes were used as 
previously described [67–69] with the exception of 
IL-5. For IL-5, the primers fIL-5_121f 5′-TGAATAG-
GCTGGTGGCAGAGA-3′, fIL-5_194r: 5′-CAGGTTC-
CCGTCGCCTATC-3′ and the probe fIL-5_143p: 
5′-FAM-CTTGGCACTGCTCTCCACTCATCGAACT-
TAMRA-3′ were designed; the reverse primer anneals 
over an exon–exon junction. The IL-5 reaction con-
tained 0.9 µM forward and reverse primers and 0.25 µM 
probe. All of the cytokine assays were performed using 
the TaqMan Fast Universal PCR Master Mix (Applied 
Biosystems) with an initial denaturation at 95 °C for 20 s 
followed by 45 cycles 95 °C for 3 s and 60 °C for 30 s. The 
V-abl Abelson murine leukemia viral oncogene homolog 
(ABL) and zeta polypeptide (YWHAZ) transcription 
levels served as reference genes for normalization, as 
previously described [70]. The calculation of the relative 
transcription levels was performed using GeNorm ver-
sion 3.5 [71]. For several samples, the transcription lev-
els of IL-10 (total n = 5; weeks 2, 3, and 11), IL-6 (total 
n = 11; weeks 1, 3 and 11) and IFN-γ (total n = 29; weeks 
2, 3, 11) were below the detection limit of the real-time 
PCR. No samples were available for cytokine measure-
ments between weeks 3 and 11.
Necropsy
Six of the cats (DR, R1, R4, P1, P2 and P5; Table 1) had 
to be euthanized for humane reasons and underwent 
necropsy and histopathological examination. Tissue sec-
tions from the lymphoma were tested to identify B and 
T cells using a CD3 T-cell marker (M7254, DAKO) and 
the B-cell marker for CD79 (M7051, DAKO; RB-90-13-P, 
Labvision, Thermo Fisher Scientific, Fremont, USA).
Statistics
Statistical analyses were performed using GraphPad 
Prism for Windows, Version 4.03 (GraphPad software, 
San Diego, CA, USA). Changes over time (same group, 
different time points) were tested using the Wilcoxon 
signed rank test for paired samples (pW) or the Fried-
man test for multiple samples (pF) with Dunn’s posttest 
(pD). Multiplicity adjusted p-values for each comparison 
in a family of comparisons were computed. The frequen-
cies were compared using the Fisher’s exact test (pFisher). 
The differences between groups A and B were compared 
using the Mann–Whitney U-test (pMWU), and the dif-
ferences between all three groups were tested using the 
Kruskal–Wallis test (pKW). A p-value  <0.05 was consid-
ered to be statistically significant.
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Additional files
Additional File 1: Table S1. Table detailing viral shedding in the saliva of 
recipient cats. Viral RNA loads detected by quantitative real‑time RT‑PCR in 
saliva collected from the recipient cats.
Additional File 2: Figure S1. Figure displaying enFeLV loads. enFeLV‑
env (a), Boxplots of enFeLV‑U3‑1 (b), enFeLV‑U3‑2 (c) and total enFeLV‑U3 
(d) loads. enFeLV loads are provided as copy numbers per feline albumin 
gene copy number.
Additional File 3: Table S2. Table detailing the results of the clinical 
evaluation of the recipient cats (lymph node size). The size of the lymph 
nodes was assessed in the 15 recipient cats throughout the observation 
period.
Additional File 4: Figure S2. Figure displaying the packed cell volume 
(PCV) of recipient cats throughout the observation period. The PCVs of the 
five cats in group A (a), group B (b) and the negative control group C (c). 
A significant change (increase) over time in PCV was observed in groups 
B and C (pF); in week 7, the cats in group A exhibited significantly lower 
PCVs compared with the control cats in group C (marked by *; pMWU = 
0.0317).
Additional File 5: Figure S3.  Figure displaying the WBC counts in recipi‑
ent cats throughout the observation period. The WBC counts of the five 
cats in group A (a), group B (b) and the negative control group C (c). A 
significant change of WBC counts was observed in group B (pF) due to a 
significant increase from week 2 to 6 (indicated by *; pD = 0.0184). In week 
2, the cats in group B exhibited significantly lower WBC counts compared 
with the control cats in group C (indicated by filled diamond; pMWU = 
0.0397).
Additional File 6: Figure S4. Figure displaying the lymphocyte counts 
in the recipient cats throughout the observation period. The lymphocyte 
counts of the five cats in group A (a), group B (b) and the negative control 
group C (c). A significant change of lymphocyte counts was observed in 
group B (pF).
Additional File 7: Figure S5.Photo of a blood smear from cat R1 (group 
B) with lymphoblastic leukemia at the time of necropsy. Lymphoblast cells 
are marked with an arrow. a) The picture displays a large lymphoblast with 
moderate amounts of basophilic cytoplasm and a large, round nucleus 
with fine chromatin patterns and several large, indistinct nucleoli. There is 
also a medium‑sized lymphocyte with moderate amounts of pale baso‑
philic cytoplasm and a round nucleus with a coarse chromatin pattern. 
b) The picture shows a medium‑sized to large lymphoblast with small 
amounts of basophilic cytoplasm and a large, round nucleus with a fine 
chromatin pattern and two prominent round nucleoli.
Additional File 8: Figure S6. Results of the FeLV subgroup PCR of cat 
P1 at the time of necropsy. The FeLV subgroups were investigated in the 
bone marrow (1) and blood plasma (2), both of which were collected 
at the time of necropsy from cat P1. The expected sizes of the positive 
controls were 1071 bp for system A (FeLV‑A), 857 bp for system B (FeLV‑B) 
and 1754 bp for system C (FeLV‑C). PCR products were analyzed on a 
1.5% agarose gel. P = positive control; N = negative control; M = Marker: 
Fermentas SM0333 (Thermo Scientific, Waltham, Massachusetts).
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